Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Strategies to Reduce Addiction Stigma Among Health Professionals

8. November 2021 aktualisiert von: Johns Hopkins Bloomberg School of Public Health

Effect of Exposure to Visual Campaigns and Narrative Vignettes on Addiction Stigma Among Health Professionals: A Randomized Experiment

The aim of this study was to evaluate the effects of exposure to stigma reduction message frames communicated by visual campaigns and narrative vignettes among a national sample of health professionals.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This randomized experiment evaluated the impact of exposure to message frames communicating the importance of non-stigmatizing language regarding addiction and the effectiveness of medication treatment for opioid use disorder delivered through a visual campaign alone or through a visual campaign in addition to a narrative vignette from the perspective of one of three messengers (a person with opioid use disorder, a clinician, or a health system leader) on attitudes toward people with opioid use disorder and medications for treating opioid use disorder among a national sample of health professionals.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

1842

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Vereinigte Staaten
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21205
        • Johns Hopkins Bloomberg School of Public Health

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • employed as health professional in the United States, including clinicians (e.g., physicians, nurses, physician assistants, pharmacists, and optometrists), technicians and technologists (e.g., laboratory technologist or technician, emergency medical technician, paramedic, licensed practical or licensed vocational nurse, medical records or health information technician, etc.), health aids and assistants (e.g., nursing aide, home health aide, medical assistant, pharmacy aide, phlebotomist, etc.)
  • participant in existing web-based survey panel (IPSOS's KnowledgeNetworks panel and partner opt-in panel)

Exclusion Criteria:

  • not employed in health profession
  • not able to complete experiment and survey in English

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Sonstiges
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Kein Eingriff: No exposure control group
This group was not exposed to any message frame.
Experimental: Words Matter - Visual Campaign
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings.
Verhalten: Words Matter - Visual Campaign
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings.
Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a person with opioid use disorder.
Verhalten: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder) Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a person with opioid use disorder
Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a clinician.
Verhalten: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a clinician working with patients with opioid use disorder
Experimental: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Participants randomized to this arm were exposed to a visual campaign communicating the importance of use of non-stigmatizing language regarding substance use disorder and opioid use disorder in clinical settings and a narrative vignette told from the perspective of a health system administrator/leader.
Verhalten: Words Matter - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Visual campaign emphasizing the importance of using non-stigmatizing language related to substance use and opioid use disorder in clinical settings combined with a narrative vignette told from the perspective of a health system administrator/leader
Experimental: Medication Treatment Works - Visual Campaign
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives.
Verhalten: Medication Treatment for Opioid Use Disorder Works - Visual Campaign
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives
Experimental: Medication Treatment Works - Visual Campaign & Narrative Vignette (Person with OUD)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a person with opioid use disorder.
Verhalten: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Person with Opioid Use Disorder)
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a person with opioid use disorder
Experimental: Medication Treatment Works - Visual Campaign & Narrative Vignette (Clinician)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a clinician.
Verhalten: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Clinician)
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a clinician who treats people with opioid use disorder
Experimental: Medication Treatment Works - Visual Campaign & Narrative Vignette (Health System Administrator)
Participants randomized to this arm were exposed to a visual campaign communicating the effectiveness of medications for treating opioid use disorder in saving lives and a narrative vignette told from the perspective of a health system administrator/leader.
Verhalten: Medication Treatment for Opioid Use Disorder Works - Visual Campaign & Narrative Vignette (Messenger: Health System Administrator)
Visual campaign emphasizing the effectiveness and value of medications to treat opioid use disorder in saving lives combined with a narrative vignette told from the perspective of a health system administrator/leader

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Rating of willingness to have person with opioid use disorder marry into their family
Zeitfenster: Measured immediately post-exposure to message frame intervention
Item from the Social Distance Scale that measures one element of stigma (desire for social distance). Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person with opioid use disorder marry into the family. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of willingness to have person with opioid use disorder as a neighbor
Zeitfenster: Measured immediately post-exposure to message frame intervention
Item from the Social Distance Scale that measures one element of stigma (desire for social distance). Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person with opioid use disorder as a neighbor. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of agreement that opioid use disorder is a medical condition
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of agreement with statement "Opioid use disorder is a chronic medical condition like diabetes mellitus" on 5-point Likert scale with 5 indicating strong disagreement and 1 indicating strong agreement. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of agreement that individuals with opioid use disorder are to blame
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of agreement with statement "Individuals with opioid use disorder only have themselves to blame for their problem" on 5-point Likert scale with 5 indicating strong disagreement and 1 indicating strong agreement. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of support for increasing government spending on opioid use disorder treatment
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of support for increasing government spending on treatment of opioid use disorder with 5 indicating strongly favoring and 1 indicating strongly opposing. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Feeling thermometer measure of warmth toward people with opioid use disorder
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of warmth felt toward people with opioid use disorder with 0 indicating extremely cold and 100 indicating extremely warm. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Stigmatizing Language - Addict
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "addict" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - Substance abuse
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "substance abuse" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - dirty
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "'dirty' in reference to the result from a drug test" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - clean
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "'clean' in reference to the result from a drug test" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - addicted baby
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "addicted baby" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - person with substance use disorder
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "person with substance use disorder" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - substance use
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "substance use" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - negative test result
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "negative test result" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - positive test result
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "positive test result" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Stigmatizing Language - baby born with neonatal opioid withdrawal syndrome
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of agreement that term "baby born with neonatal opioid withdrawal syndrome" appropriate in a clinical care setting with 1 indicating strongly agree (that term is appropriate) and 5 indicating strongly disagree (that term is appropriate). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Willingness to sign pledge committing to using non-stigmatizing language
Zeitfenster: Measured immediately post-exposure to message frame intervention
Binary (yes/no) measure of whether participant is willing to sign a pledge committing to using non-stigmatizing language related to substance use disorder in clinical settings. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Perception of opioid use disorder treatment effectiveness
Zeitfenster: Measured immediately post-exposure to message frame intervention
Participant perception of whether there is a treatment for opioid use disorder that is effective for a long period of time (three close-ended response options: yes, there is a treatment; no, there isn't such a treatment; don't know). Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of willingness to have person taking medication marry into their family
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of willingness to have person taking medication to treat opioid use disorder marry into family. Item from the Social Distance Scale that measures one element of stigma (desire for social distance). Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person taking medication to treat opioid use disorder marry into the family. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of willingness to have person taking medication marry as a neighbor
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of willingness to have person taking medication to treat opioid use disorder as a neighbor. Item from the Social Distance Scale that measures one element of stigma (desire for social distance). Measured on 5-point Likert scale with 5 indicating greater unwillingness and 1 indicating greater willingness to have a person taking medication to treat opioid use disorder as a neighbor. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of strength/weakness of person taking medication
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of strength/weakness of person taking medication to treat opioid use disorder on 5-point Likert scale with 5 indicating strong and 1 indicating weak. This is a semantic differential measure. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Rating of agreement that recovery is possible
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of agreement with statement "Most people with opioid use disorder will, with medication treatment, get well and return to productive lives" on a 5-point Likert scale with 5 indicating strongly disagree and 1 indicating strongly agree. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention
Feeling thermometer measure of warmth toward people taking medication
Zeitfenster: Measured immediately post-exposure to message frame intervention
Rating of warmth felt toward people taking medication to treat opioid use disorder with 0 indicating extremely cold and 100 indicating extremely warm. Measured via survey questionnaire.
Measured immediately post-exposure to message frame intervention

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Johns Hopkins Bloomberg School of Public Health

Ermittler

  • Hauptermittler: Alene Kennedy-Hendricks, PhD, Johns Hopkins Bloomberg School of Public Health

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

13. November 2020

Primärer Abschluss (Tatsächlich)

30. November 2020

Studienabschluss (Tatsächlich)

30. November 2020

Studienanmeldedaten

Zuerst eingereicht

28. Oktober 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

8. November 2021

Zuerst gepostet (Tatsächlich)

19. November 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

19. November 2021

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

8. November 2021

Zuletzt verifiziert

1. November 2021

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • IRB14743

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren